NLS Pharmaceutics AG has announced a significant milestone in collaboration with Kadimastem Ltd. and iTolerance, Inc., as the Israel-U.S. Binational Industrial Research and Development Foundation (BIRD Foundation) approved a new milestone-based funding payment. The grant of approximately NIS 564,400 ($166,000 USD) is part of a larger support package totaling nearly NIS 3 million ($882,352 USD) to date. This funding is allocated to advance the development of iTOL-102, a novel cell therapy aimed at curing Type 1 diabetes without the need for life-long immunosuppression. The approval follows a successful Pre-IND meeting with the U.S. FDA, paving the way for First-in-Human clinical trials. The collaboration highlights the significant scientific progress and strategic partnership between NLS Pharmaceutics, Kadimastem, and iTolerance.